164 related articles for article (PubMed ID: 12452024)
1. [Phase II clinical study of topotecan hydrochloride in patients with recurrent advanced ovarian cancer].
Li JD; Guan ZZ; Liu JH; Xin XY; Cui Y; Huang CJ; Liu FY; Song L; Bian ML; Zhou QH
Ai Zheng; 2002 Apr; 21(4):416-20. PubMed ID: 12452024
[TBL] [Abstract][Full Text] [Related]
2. [Single topotecan or in combination with other chemotherapeutic agents for 18 recurrent advanced ovarian cancer patients].
Li H; Liu L; Zhang W
Zhonghua Zhong Liu Za Zhi; 2001 Nov; 23(6):513-5. PubMed ID: 11859726
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
Markman M; Blessing JA; Alvarez RD; Hanjani P; Waggoner S; Hall K
Gynecol Oncol; 2000 Apr; 77(1):112-5. PubMed ID: 10739699
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of topotecan in the treatment of small cell lung cancer and recurrent ovarian cancer].
Feng F; He X; Shi Y
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):155-8. PubMed ID: 11783024
[TBL] [Abstract][Full Text] [Related]
6. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
7. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.
Markman M; Blessing JA; DeGeest K; Morgan M; Look KY; Herzog TJ; Rose PG
Gynecol Oncol; 1999 Dec; 75(3):444-6. PubMed ID: 10600304
[TBL] [Abstract][Full Text] [Related]
8. Long time therapy with topotecan in patients with recurrence of ovarian carcinoma.
Möbus V; Pfaff PN; Volm T; Kreienberg R; Kaubitzsch S
Anticancer Res; 2001; 21(5):3551-6. PubMed ID: 11848522
[TBL] [Abstract][Full Text] [Related]
9. Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer.
Gore M; Rustin G; Schüller J; Lane SR; Hearn S; Beckman RA; Ross G
Br J Cancer; 2001 Apr; 84(8):1043-6. PubMed ID: 11308251
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
Gordon AN; Tonda M; Sun S; Rackoff W;
Gynecol Oncol; 2004 Oct; 95(1):1-8. PubMed ID: 15385103
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A
Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
[TBL] [Abstract][Full Text] [Related]
13. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
Largillier R; Valenza B; Ferrero JM; Novo C; Creisson A; Lesbats G; Mari V; Hebert C; Chamorey E
Oncology; 2007; 73(3-4):177-84. PubMed ID: 18418010
[TBL] [Abstract][Full Text] [Related]
14. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
Downs LS; Judson PL; Argenta PA; Ghebre R; Geller MA; Bliss RL; Boente MP; Nahhas WA; Abu-Ghazaleh SZ; Chen MD; Carson LF
Cancer; 2008 Jan; 112(2):331-9. PubMed ID: 18058810
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
Safra T; Menczer J; Bernstein R; Shpigel S; Inbar MJ; Grisaru D; Golan A; Levy T
Gynecol Oncol; 2007 Apr; 105(1):205-10. PubMed ID: 17239430
[TBL] [Abstract][Full Text] [Related]
17. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients.
Denschlag D; Watermann D; Hörig K; Kissel C; Tempfer C; Gitsch G
Anticancer Res; 2004; 24(2C):1267-9. PubMed ID: 15154658
[TBL] [Abstract][Full Text] [Related]
18. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
O'Malley DM; Azodi M; Makkenchery A; Tangir J; McAlpine J; Kelly M; Schwartz P; Rutherford T
Gynecol Oncol; 2005 Aug; 98(2):242-8. PubMed ID: 15992916
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
Spannuth WA; Leath CA; Huh WK; Barnes MN; Davidson SA; Kilgore LC; Partridge EE; Austin JM; Alvarez RD
Gynecol Oncol; 2007 Mar; 104(3):591-5. PubMed ID: 17045635
[TBL] [Abstract][Full Text] [Related]
20. [Early results of topotecan therapy in patients with recurrent ovarian cancer].
Lehoczky O; Bagaméri A; Lehoczky G; Pulay T
Orv Hetil; 2002 Apr; 143(16):825-8. PubMed ID: 12053883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]